UW GI Flashcards
Inhibit the rate-limiting step in cholesterol biosynthesis (HMG-CoS reductase)
Statins
SE statins
Hepatotoxicity, muscle toxicity
Increase lipoprotein lipase activity,
decrease hepatic VLDL secretion,
increase HDL synthesis
Fibrates (Gemfibrozil, fenofibrate)
SE fibrates
muscle toxicity, esp when combined with statins; gallstones
Bind bile acids in the intestine; decrease reabsorption and increase de novo synthesis form cholesterol
Bile acid sequestrants (cholestyramine, colestipol, colesevelam)
Bile acid sequestrants SE
nausea, bloating, cramping; decreased absorption of digoxin, warfarin, and fat-soluble vitamins
Decreased lipolysis in adipose tissue causing decreased VLDL synthesis, increased HDL by reducing clearance
Niacin
Niacin SE
flushing, warmth, pruritius, hepatotoxicity
Decreased cholesterol absorption at the brush border of the intestine
Ezetimibe
Ezetimibe SE
Increased hepatotoxicity when coadministered with statins
Decreased synthesis of mycolic acid. Bacterial catalase-peroxidase (encoded by KatG) needed to convert this drug to its active metabolite.
Isoniazid (INH)
INH side effects
Neurotoxicity, hepatotoxicity, Pyroxidine (B6) can prevent neurotoxicity, lupus.
The biologically active form of pantothenic acid is
coenzyme A
Coenzyme A binds with oxaloacetate in the first step of the Krebs cycle to form
citrate and then succinyl-CoA
Artery behind lesser curvature of stomach
L. gastric
Third part of duodenum is in close association with
uncinate process of pancreas, SMA, + SMV
Pts receiving TPN are at risk for biliary stones d/t
decreased CCK release due to the lack of enteral stimulation
mutations associated with colitis-associated carcinoma are
early p53 and late APC (opposite)